CN106459016B - 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药 - Google Patents

1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药 Download PDF

Info

Publication number
CN106459016B
CN106459016B CN201580023347.0A CN201580023347A CN106459016B CN 106459016 B CN106459016 B CN 106459016B CN 201580023347 A CN201580023347 A CN 201580023347A CN 106459016 B CN106459016 B CN 106459016B
Authority
CN
China
Prior art keywords
disease
compound
sap
amyloidosis
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580023347.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459016A (zh
Inventor
A.丹尼斯
O.米尔盖特
J.图姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN106459016A publication Critical patent/CN106459016A/zh
Application granted granted Critical
Publication of CN106459016B publication Critical patent/CN106459016B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580023347.0A 2014-04-29 2015-04-27 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药 Expired - Fee Related CN106459016B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1407506.3 2014-04-29
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound
PCT/EP2015/058998 WO2015165833A1 (en) 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Publications (2)

Publication Number Publication Date
CN106459016A CN106459016A (zh) 2017-02-22
CN106459016B true CN106459016B (zh) 2019-11-01

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580023347.0A Expired - Fee Related CN106459016B (zh) 2014-04-29 2015-04-27 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药

Country Status (26)

Country Link
US (3) US9701668B2 (enExample)
EP (1) EP3137457B1 (enExample)
JP (1) JP6445046B2 (enExample)
KR (1) KR20160145617A (enExample)
CN (1) CN106459016B (enExample)
AR (1) AR100204A1 (enExample)
AU (1) AU2015252184B2 (enExample)
BR (1) BR112016025129A2 (enExample)
CA (1) CA2947060C (enExample)
CL (1) CL2016002721A1 (enExample)
CR (1) CR20160508A (enExample)
DO (1) DOP2016000292A (enExample)
EA (1) EA032129B1 (enExample)
ES (1) ES2731253T3 (enExample)
GB (1) GB201407506D0 (enExample)
IL (2) IL248249A0 (enExample)
MA (1) MA39406B1 (enExample)
MX (1) MX2016014246A (enExample)
MY (1) MY191088A (enExample)
PE (1) PE20161558A1 (enExample)
PH (1) PH12016502006B1 (enExample)
SG (1) SG11201608371RA (enExample)
TW (1) TWI676624B (enExample)
UA (1) UA119871C2 (enExample)
UY (1) UY36098A (enExample)
WO (1) WO2015165833A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1604892A (zh) * 2001-12-14 2005-04-06 弗·哈夫曼-拉罗切有限公司 D－脯氨酸的前药

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT915088E (pt) 1997-10-31 2003-01-31 Hoffmann La Roche Derivados de d-prolina
EP1636240A1 (en) 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
EP1870412A4 (en) 2005-04-12 2009-12-30 Meiji Seika Kaisha 2-THIOETHENYLCARBAPENEM DERIVATIVE
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1604892A (zh) * 2001-12-14 2005-04-06 弗·哈夫曼-拉罗切有限公司 D－脯氨酸的前药

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Recent Advances in Oral Prodrug Discovery;Aesop Cho;《ANNUAL REPORTS IN MEDICINAL CHEMISTRY》;20061231;第41卷;第395-407页 *

Also Published As

Publication number Publication date
TW201625598A (zh) 2016-07-16
EP3137457A1 (en) 2017-03-08
BR112016025129A2 (pt) 2017-08-15
PH12016502006A1 (en) 2016-12-19
IL279120A (en) 2021-01-31
IL248249A0 (en) 2016-11-30
JP6445046B2 (ja) 2018-12-26
AR100204A1 (es) 2016-09-21
US20180099955A1 (en) 2018-04-12
CA2947060C (en) 2023-09-26
SG11201608371RA (en) 2016-11-29
WO2015165833A1 (en) 2015-11-05
UA119871C2 (uk) 2019-08-27
US20170267665A1 (en) 2017-09-21
JP2017514829A (ja) 2017-06-08
ES2731253T3 (es) 2019-11-14
DOP2016000292A (es) 2017-11-15
PE20161558A1 (es) 2017-01-06
AU2015252184B2 (en) 2017-11-02
US9873686B2 (en) 2018-01-23
UY36098A (es) 2015-11-30
EP3137457B1 (en) 2019-04-17
US20160075694A1 (en) 2016-03-17
US10597385B2 (en) 2020-03-24
TWI676624B (zh) 2019-11-11
MX2016014246A (es) 2017-02-06
AU2015252184A1 (en) 2016-10-27
EA032129B1 (ru) 2019-04-30
EA201692185A1 (ru) 2017-06-30
CR20160508A (es) 2017-03-10
US9701668B2 (en) 2017-07-11
GB201407506D0 (en) 2014-06-11
MY191088A (en) 2022-05-30
KR20160145617A (ko) 2016-12-20
MA39406B1 (fr) 2018-04-30
CN106459016A (zh) 2017-02-22
PH12016502006B1 (en) 2016-12-19
MA39406A1 (fr) 2017-07-31
CL2016002721A1 (es) 2017-01-20
CA2947060A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
EP3953361A1 (en) Compounds and methods for the treatment of covid-19
EP3843768A1 (en) Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
US9737505B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
CN106459016B (zh) 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药
CN117940407A (zh) 降低免疫不耐受和治疗自身免疫病症的组合物和方法
CN114025766A (zh) 用于抑制gapdh的噁噻嗪化合物
WO2023165459A1 (en) Compounds as sars-cov-2 inhibitors
JP7053762B2 (ja) Ｓａｐ枯渇剤としてのｄ－プロリン誘導体
US20220305006A1 (en) Compositions and methods for the treatment of neurological diseases and disorders
US20240398792A1 (en) Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
HK40067738A (en) Oxathiazin compounds for inhibiting gapdh
HK40067738B (zh) 用於抑制gapdh的恶噻嗪化合物
GB2467560A (en) Dual calpain-ROS inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191101